ARS Pharmaceuticals (SPRY) Current Leases (2020 - 2025)
ARS Pharmaceuticals (SPRY) reported Current Leases of $583000.0 for Q3 2025, up 471.57% on a YoY basis from $102000.0 in Q3 2024, and down 1.02% sequentially from $589000.0 in Q2 2025.
ARS Pharmaceuticals (SPRY) Current Leases (2020 - 2025) Analysis & Trends
ARS Pharmaceuticals (SPRY) has 6 years of Current Leases data on file, last reported at $583000.0 in Q3 2025.
- For the quarter ending Q3 2025, Current Leases rose 471.57% year-over-year to $583000.0; the trailing twelve-month figure through Sep 2025 stood at $583000.0 (up 471.57% YoY), and the FY2024 full-year result was $42000.0, down 82.28% from the prior year.
- Current Leases fell to $583000.0 in Q3 2025, from $589000.0 in the prior quarter.
- In the past five years, Current Leases ranged from a high of $1.1 million in Q1 2022 to a low of $42000.0 in Q4 2024.
- A 5-year average of $435315.8 and a median of $233000.0 in 2023 frame the typical range for Current Leases.
- Across the five-year window, Current Leases tumbled 83.93% in 2021 and jumped 471.57% in 2025, its largest moves.
- Tracing SPRY's Current Leases over 5 years: stood at $144000.0 in 2021, then soared by 59.72% to $230000.0 in 2022, then rose by 3.04% to $237000.0 in 2023, then plunged by 82.28% to $42000.0 in 2024, then surged by 1288.1% to $583000.0 in 2025.
- Business Quant data shows SPRY's Current Leases at $583000.0 in Q3 2025, $589000.0 in Q2 2025, and $73000.0 in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Leases (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 531,233.95 |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 20.58 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 872,589.03 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 720.00 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 11.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 16.61 Mn |
| 10 | ARS Pharmaceuticals | 595.78 Mn | 394.81 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 583,000.00 |
| Jun 30, 2025 | 589,000.00 |
| Mar 31, 2025 | 73,000.00 |
| Dec 31, 2024 | 42,000.00 |
| Sep 30, 2024 | 102,000.00 |
| Jun 30, 2024 | 160,000.00 |
| Mar 31, 2024 | 217,000.00 |
| Dec 31, 2023 | 237,000.00 |
| Sep 30, 2023 | 235,000.00 |
| Jun 30, 2023 | 233,000.00 |
| Mar 31, 2023 | 232,000.00 |
| Dec 31, 2022 | 230,000.00 |
| Sep 30, 2022 | 215,000.00 |
| Jun 30, 2022 | 881,000.00 |
| Mar 31, 2022 | 1.12 Mn |
| Dec 31, 2021 | 144,000.00 |
| Sep 30, 2021 | 1.09 Mn |
| Jun 30, 2021 | 958,000.00 |
| Mar 31, 2021 | 927,000.00 |
| Dec 31, 2020 | 896,000.00 |